-
Overview
Date & Location
3/10/23 – 3/10/24 12:00 AM CST Online
Overview
On the third anniversary of COVID-19 in the U.S., Dr. Patterson talks with Dr. Bowling about how surveillance of COVID has changed, what the numbers mean, whether masking is still needed, and the consequences of the end of the federal emergency declaration.
Target Audience
This educational activity is designed to meet the educational goals of physicians and other healthcare professionals specializing in infectious diseases, family and community medicine, internal medicine, emergency medicine, and all those involved with the management of patients with coronavirus.
Learning Objectives for the Episode 11
- Decribe epidemiology of current phase of the pandemic
- Describe how surveillance and reporting for COVID cases is currently being done
- List current outpatient treatment for COVID-19
- List circumstances when a mask may still be needed
- Describe the consequences of the federal COVID emergency declaration ending
Program Registration Information
Registration Fees - $0.00
Continuing Medical Education Education Credit - Accreditation and Designation Statement
¸£Àû͵ÅÄ91 ÉîÒ¹¸£Àû Science Center San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
¸£Àû͵ÅÄ91 ÉîÒ¹¸£Àû Science Center San Antonio designates this enduring material for a maximum of .50 AMA PRA Category 1 Creditsâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Certificate of Attendance
Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance.
Credit may be obtained upon successful completion of the activity¸£Àû͵ÅÄ91 ÉîÒ¹¸£Àû evaluation.
Release date: 03/10/2023 Credits expire: 03/10/2024
-
Faculty
Jan E. Patterson, MD, MS, MACP
FIDSA, FSHEA, CHCP
Professor of Medicine/Infectious Diseases and Pathology
Associate Dean for Quality & Lifelong Learning
Joe R. and Teresa Lozano Long School of Medicine
¸£Àû͵ÅÄ91 ÉîÒ¹¸£ÀûDr. Patterson is a professor of Medicine/Infectious Disease and Associate Dean for Quality & Lifelong Learning at The Joe. R and Teresa Lozano Long School of Medicine, ¸£Àû͵ÅÄ91 ÉîÒ¹¸£Àû. She is a clinician and a healthcare epidemiologist and has served on the Infectious Diseases Society of America Board of Directors and is Past President of the Society of Healthcare Epidemiology of America. She is a longtime infectious disease consultant to the Southwest Texas Regional Advisory Council (STRAC), has served on the CDC¸£Àû͵ÅÄ91 ÉîÒ¹¸£Àû Healthcare Infection Practices Advisory Committee and has been a consultant to the City of San Antonio Metro Health Department. She has been a site principal investigator for new antimicrobial agents and was a co-investigator for the NIH Adaptive COVID-19 Treatment Trial (ACTT) studies, NIH Accelerating COVID-10 Therapeutic Interventions and Vaccines studies (ACTIV-6) and a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at ¸£Àû͵ÅÄ91 ÉîÒ¹¸£Àû and University Hospital.
Financial Disclosures
Dr. Jan Patterson has disclosed that she is a NIH ACTT co-investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial and receives honorarium from Pfizer.
Jason Bowling, MD
Associate Professor of Medicine/Infectious Diseases
Joe R. and Teresa Lozano Long School of Medicine
¸£Àû͵ÅÄ91 ÉîÒ¹¸£ÀûDr. Bowling is an Associate Professor of Medicine, Division of Infectious Diseases at the Joe R. and Teresa Lozano Long School of Medicine, ¸£Àû͵ÅÄ91 ÉîÒ¹¸£Àû. He is a clinician and a healthcare epidemiologist at University Health. He is also an investigator for the Adaptive COVID-19 Treatment Trial (ACTT) conducted at University Hospital and a sub-investigator for the Novavax SARS-CoV-2 vaccine trial at ¸£Àû͵ÅÄ91 ÉîÒ¹¸£Àû and University Hospital.
Financial Disclosures
Dr. Jason Bowling has disclosed that he is an NIH ACTT co- investigator and sub-investigator for the Novavax SARS-CoV-2 vaccine trial and was an advisor to Eli Lilly.
